A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)

Trial Profile

A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs LJPC 501 (Primary)
  • Indications Hypotension
  • Focus Registrational; Therapeutic Use
  • Acronyms ATHOS-3
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 21 Dec 2017 According to a La Jolla Pharmaceutical Company media release, the U.S. Food and Drug Administration (FDA) has approved Giapreza (angiotensin II) to increase blood pressure in adults with septic or other distributive shock.
    • 26 Oct 2017 According to a La Jolla Pharmaceutical Company media release, data from the study was presented during the 30th European Society of Intensive Care Medicine Annual Congress.
    • 20 Sep 2017 Results of a pre-specified analysis of this trial were published onlline, according to a La Jolla Pharmaceutical Company.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top